Literature DB >> 10049295

Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides.

E J Helmerhorst1, I M Reijnders, W van't Hof, I Simoons-Smit, E C Veerman, A V Amerongen.   

Abstract

The present study shows that a number of basic antifungal peptides, including human salivary histatin 5, a designed histatin analog designated dhvar4, and a peptide from frog skin, PGLa, are active against amphotericin B-resistant Candida albicans, Candida krusei, and Aspergillus fumigatus strains and against a fluconazole-resistant Candida glabrata isolate.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10049295      PMCID： PMC89188     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Failure of all antifungal therapy for infection due to Candida albicans: a new AIDS-related problem?

Authors:  D Landman; G Saurina; J M Quale
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

Review 2.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

Review 3.  Molecular mechanisms of drug resistance in fungi.

Authors:  H Vanden Bossche; P Marichal; F C Odds
Journal:  Trends Microbiol       Date:  1994-10       Impact factor: 17.079

4.  Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia.

Authors:  F S Nolte; T Parkinson; D J Falconer; S Dix; J Williams; C Gilmore; R Geller; J R Wingard
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  Amphotericin B resistance testing of Candida spp.: a comparison of methods.

Authors:  D Law; C B Moore; D W Denning
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

6.  Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation.

Authors:  S L Kelly; D C Lamb; D E Kelly; N J Manning; J Loeffler; H Hebart; U Schumacher; H Einsele
Journal:  FEBS Lett       Date:  1997-01-02       Impact factor: 4.124

Review 7.  New and emerging yeast pathogens.

Authors:  K C Hazen
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

8.  Studies of the mechanism of human salivary histatin-5 candidacidal activity with histatin-5 variants and azole-sensitive and -resistant Candida species.

Authors:  H Tsai; L A Bobek
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

9.  Synthetic histatin analogues with broad-spectrum antimicrobial activity.

Authors:  E J Helmerhorst; W Van't Hof; E C Veerman; I Simoons-Smit; A V Nieuw Amerongen
Journal:  Biochem J       Date:  1997-08-15       Impact factor: 3.857

10.  Human salivary histatin-5 exerts potent fungicidal activity against Cryptococcus neoformans.

Authors:  H Tsai; L A Bobek
Journal:  Biochim Biophys Acta       Date:  1997-10-20
View more
  31 in total

1.  Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5.

Authors:  D M Rothstein; P Spacciapoli; L T Tran; T Xu; F D Roberts; M Dalla Serra; D K Buxton; F G Oppenheim; P Friden
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

Review 2.  How does it kill?: understanding the candidacidal mechanism of salivary histatin 5.

Authors:  Sumant Puri; Mira Edgerton
Journal:  Eukaryot Cell       Date:  2014-06-20

3.  The human salivary peptide histatin 5 exerts its antifungal activity through the formation of reactive oxygen species.

Authors:  E J Helmerhorst; R F Troxler; F G Oppenheim
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

4.  Typing of Candida glabrata in clinical isolates by comparative sequence analysis of the cytochrome c oxidase subunit 2 gene distinguishes two clusters of strains associated with geographical sequence polymorphisms.

Authors:  G F Sanson; M R Briones
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

5.  Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (sterol 14α-demethylase) doxycycline-regulated mutant and screening of the azole sensitivity of Aspergillus fumigatus isoenzymes CYP51A and CYP51B.

Authors:  Claire M Martel; Josie E Parker; Andrew G S Warrilow; Nicola J Rolley; Steven L Kelly; Diane E Kelly
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

6.  The P-113 fragment of histatin 5 requires a specific peptide sequence for intracellular translocation in Candida albicans, which is independent of cell wall binding.

Authors:  Woong Sik Jang; Xuewei Serene Li; Jianing N Sun; Mira Edgerton
Journal:  Antimicrob Agents Chemother       Date:  2007-11-12       Impact factor: 5.191

7.  Human antimicrobial peptides' antifungal activity against Aspergillus fumigatus.

Authors:  A Lupetti; J T van Dissel; C P J M Brouwer; P H Nibbering
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-20       Impact factor: 3.267

8.  Candidacidal activity of synthetic peptides based on the antimicrobial domain of the neutrophil-derived protein, CAP37.

Authors:  H Anne Pereira; Irina Tsyshevskaya-Hoover; Heather Hinsley; Sreemathi Logan; Melissa Nguyen; Thuy-Trang Nguyen; Jan Pohl; Karen Wozniak; Paul L Fidel
Journal:  Med Mycol       Date:  2010-03       Impact factor: 4.076

9.  Development and In Vivo Evaluation of a Novel Histatin-5 Bioadhesive Hydrogel Formulation against Oral Candidiasis.

Authors:  Eric F Kong; Christina Tsui; Heather Boyce; Ahmed Ibrahim; Stephen W Hoag; Amy J Karlsson; Timothy F Meiller; Mary Ann Jabra-Rizk
Journal:  Antimicrob Agents Chemother       Date:  2015-11-23       Impact factor: 5.191

10.  Susceptibility of Candida dubliniensis to salivary histatin 3.

Authors:  Deirdre H Fitzgerald; David C Coleman; Brian C O'Connell
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.